{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+the+Endometrium&page=2", "query": { "condition": "Adenocarcinoma of the Endometrium", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+the+Endometrium&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-27T21:11:09.362Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05325866", "title": "A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Bemarituzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 260, "start_date": "2022-09-23", "completion_date": "2026-01-28", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-06-27T21:11:09.362Z", "location_count": 10, "location_summary": "Duarte, California • Orange, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05325866" }, { "nct_id": "NCT05548296", "title": "A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma" ], "interventions": [ { "name": "ACR-368", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "OncoSignature", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Acrivon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 350, "start_date": "2022-08-29", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-06-27T21:11:09.362Z", "location_count": 69, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 56 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05548296" }, { "nct_id": "NCT03120624", "title": "VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Endometrial Carcinoma", "Recurrent Endometrial Adenocarcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Endometrial Clear Cell Adenocarcinoma", "Recurrent Endometrial Endometrioid Adenocarcinoma", "Recurrent Endometrial Mixed Cell Adenocarcinoma", "Recurrent Endometrial Serous Adenocarcinoma", "Recurrent Endometrial Undifferentiated Carcinoma", "Recurrent Uterine Corpus Carcinosarcoma", "Stage IV Uterine Corpus Cancer AJCC v7" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorine F 18 Tetrafluoroborate", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" }, { "name": "Technetium Tc-99m Sodium Pertechnetate", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 34, "start_date": "2017-09-15", "completion_date": "2028-01-01", "has_results": true, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-06-27T21:11:09.362Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03120624" }, { "nct_id": "NCT00820898", "title": "Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Recurrent Uterine Corpus Carcinoma" ], "interventions": [ { "name": "Gemcitabine Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2009-02", "completion_date": null, "has_results": true, "last_update_posted_date": "2017-12-29", "last_synced_at": "2026-06-27T21:11:09.362Z", "location_count": 20, "location_summary": "Hartford, Connecticut • Chicago, Illinois • Decatur, Illinois + 16 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00820898" }, { "nct_id": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB0123667", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 604, "start_date": "2022-07-05", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-06-27T21:11:09.362Z", "location_count": 19, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05238922" }, { "nct_id": "NCT01184053", "title": "Trisenox® in Women With Metastatic Endometrial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Carcinoma" ], "interventions": [ { "name": "Arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2010-03", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-06-27T21:11:09.362Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01184053" }, { "nct_id": "NCT06730347", "title": "A Study of Lorigerlimab in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Platinum-resistant Ovarian Cancer", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Clear Cell Adenocarcinoma of Ovary", "Clear Cell Adenocarcinoma of Vulva", "Clear Cell Adenocarcinoma of Vagina", "Clear Cell Adenocarcinoma of Cervix", "Clear Cell Adenocarcinoma of Uterus", "Clear Cell Adenocarcinoma of Fallopian Tube", "Clear Cell Adenocarcinoma of Peritoneum", "Endometrial Cancer" ], "interventions": [ { "name": "Lorigerlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 80, "start_date": "2025-05-01", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-06-27T21:11:09.362Z", "location_count": 7, "location_summary": "Los Angeles, California • New Orleans, Louisiana • Grand Rapids, Michigan + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06730347" }, { "nct_id": "NCT00002493", "title": "Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer", "Psychosocial Effects of Cancer and Its Treatment" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "low-LET photon therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": null, "start_date": "1992-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-02-14", "last_synced_at": "2026-06-27T21:11:09.362Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002493" }, { "nct_id": "NCT00025467", "title": "Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenoacanthoma", "Endometrial Adenocarcinoma", "Endometrial Adenosquamous Cell Carcinoma", "Endometrial Clear Cell Carcinoma", "Endometrial Papillary Serous Carcinoma", "Recurrent Endometrial Carcinoma" ], "interventions": [ { "name": "thalidomide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 60, "start_date": "2001-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-06-27T21:11:09.362Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025467" }, { "nct_id": "NCT00005830", "title": "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Stage III Uterine Corpus Cancer", "Stage IV Uterine Corpus Cancer" ], "interventions": [ { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 31, "start_date": "2000-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-12-31", "last_synced_at": "2026-06-27T21:11:09.362Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005830" } ] }